ImmuCell Stock

ImmuCell P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of ImmuCell (ICCC) as of Aug 10, 2026 is 48.74. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -553.71 — a change of -108.80% (higher).

P/FCF

48.74

YoY

-108.80%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of ImmuCell is 2026 48.74 . P/FCF (Price-to-Free-Cash-Flow Ratio) of ImmuCell was 2025 -553.71 . It decreases by -108.80% higher compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of ImmuCell is 48.74 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of ImmuCell changed from -553.71 to 48.74, representing a -108.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s ImmuCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — ImmuCell

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — ImmuCell